{"id":18866,"date":"2024-03-19T13:02:16","date_gmt":"2024-03-19T07:32:16","guid":{"rendered":"https:\/\/www.fitterfly.com\/blog\/?p=18866"},"modified":"2024-03-19T13:02:16","modified_gmt":"2024-03-19T07:32:16","slug":"beyond-a1c-new-metrics-and-tech-supported-goals","status":"publish","type":"post","link":"https:\/\/www.fitterfly.com\/blog\/beyond-a1c-new-metrics-and-tech-supported-goals\/","title":{"rendered":"Beyond A1C: New Metrics and Tech-Supported Goals"},"content":{"rendered":"

Abstract:<\/b><\/h2>\n

Diabetes care is shifting beyond reliance on the A1c test with the advancement in technologies and inventions of the latest biomarkers. The limitations of the HbA1c test in capturing daily fluctuations, and the impact of existing medical conditions have led to the development of TIR, TAR, flash-glucose sensing technology, and 1,5-Anhydroglucitol measurement as modern-day metrics for diabetes care.<\/p>\n

Why are doctors moving beyond the A1c test for diabetes Management?<\/b><\/h2>\n

As technology propels healthcare into unprecedented innovations, the <\/span>diabetes care landscape is evolving rapidly, opening doors to novel approaches and personalised strategies. Earlier physicians perceived the HbA1C test as a cornerstone in diabetes management, providing a crucial snapshot of average blood glucose levels during the previous two to three months. However, its limitations are increasingly evident in capturing the nuances of daily fluctuations and individualised treatment responses. This realisation has sparked a paradigm shift within the medical community, prompting a quest for more comprehensive and precise metrics to drive diabetes care.<\/span><\/p>\n

In this blog, we explore the emerging metrics and the transformative role of technology in diabetes management. From time in target range to glucose exposure, flash-glucose sensing technology, 1,5-Anhydroglucitol measurement and construction of the Q-Score, we delve into the emerging arsenals for advanced <\/span>diabetes care.<\/p>\n

Limitation of HbA1c in Glucose Monitoring<\/b><\/h2>\n

HbA1c refers to the glycated haemoglobin at the N-terminal valine residue of adult haemoglobin\u2019s \u03b2 chain. High-performance liquid chromatography and immunoassays are the two most common methods of determining the HbA1c level. However, several factors like<\/span> iron deficiency anaemia, folate deficiency anaemia, B12 deficiency anaemia, excessive alcohol intake, and asplenia<\/span><\/a> can impact the accuracy and reliability of HbA1c values. These factors increase the erythrocyte life cycle and may result in falsely high HbA1c values.<\/span><\/p>\n

Similarly, factors like splenomegaly, pregnancy, acute and chronic blood loss, and hemolytic anaemia may shorten erythrocytes’ life cycle and lead to falsely low HbA1c results. Moreover, comorbidities like chronic kidney disease impact HbA1c values especially when the estimated glomerular filtration rate decreases <\/span>below 30 mL\/min per 1.73 m<\/span><\/a>. The above challenges led to the evolution of alternative biomarkers for determining the blood sugar level.<\/span><\/p>\n

Latest Metrics for Measuring Blood Sugar Values<\/b><\/h2>\n

Physicians are now relying on advanced glucose tests like t<\/span>ime in the target range, flash-glucose sensing technology, 1,5-Anhydroglucitol measurement and construction of the Q-Score to navigate the complexities of diabetes management with greater confidence and efficacy.<\/span><\/p>\n